MGO One Seven LLC Buys Shares of 17,460 ClearPoint Neuro, Inc. (NASDAQ:CLPT)

MGO One Seven LLC acquired a new stake in shares of ClearPoint Neuro, Inc. (NASDAQ:CLPT - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor acquired 17,460 shares of the company's stock, valued at approximately $269,000. MGO One Seven LLC owned approximately 0.06% of ClearPoint Neuro at the end of the most recent quarter.

A number of other hedge funds also recently bought and sold shares of the business. R Squared Ltd acquired a new position in ClearPoint Neuro during the fourth quarter worth $32,000. AlphaQuest LLC purchased a new stake in shares of ClearPoint Neuro in the fourth quarter valued at about $80,000. Barclays PLC increased its position in ClearPoint Neuro by 24.3% during the third quarter. Barclays PLC now owns 5,674 shares of the company's stock worth $64,000 after purchasing an additional 1,109 shares during the last quarter. Tower Research Capital LLC TRC purchased a new position in ClearPoint Neuro during the fourth quarter worth about $93,000. Finally, JPMorgan Chase & Co. boosted its holdings in ClearPoint Neuro by 58.7% in the 3rd quarter. JPMorgan Chase & Co. now owns 9,770 shares of the company's stock valued at $110,000 after purchasing an additional 3,612 shares during the last quarter. Institutional investors and hedge funds own 30.08% of the company's stock.

Wall Street Analyst Weigh In

CLPT has been the subject of several recent analyst reports. Stifel Nicolaus raised their target price on ClearPoint Neuro from $19.00 to $25.00 and gave the stock a "buy" rating in a research note on Tuesday, April 1st. Lake Street Capital upped their target price on shares of ClearPoint Neuro from $17.00 to $30.00 and gave the company a "buy" rating in a research report on Tuesday, January 21st. Finally, B. Riley lifted their price target on shares of ClearPoint Neuro from $15.00 to $20.00 and gave the company a "buy" rating in a research report on Tuesday, January 28th.

ClearPoint Neuro Stock Performance

CLPT stock traded up $0.52 during midday trading on Friday, reaching $14.43. 220,413 shares of the company were exchanged, compared to its average volume of 225,817. The company has a market cap of $403.75 million, a price-to-earnings ratio of -20.91 and a beta of 0.97. ClearPoint Neuro, Inc. has a 1-year low of $5.11 and a 1-year high of $19.22. The stock's 50-day simple moving average is $12.93 and its 200 day simple moving average is $14.17.

ClearPoint Neuro (NASDAQ:CLPT - Get Free Report) last posted its earnings results on Wednesday, February 26th. The company reported ($0.20) earnings per share for the quarter, missing the consensus estimate of ($0.15) by ($0.05). The firm had revenue of $7.77 million during the quarter, compared to analysts' expectations of $8.23 million. ClearPoint Neuro had a negative net margin of 59.64% and a negative return on equity of 62.10%. On average, research analysts anticipate that ClearPoint Neuro, Inc. will post -0.66 earnings per share for the current year.

About ClearPoint Neuro

ClearPoint Neuro, Inc operates as a medical device company primarily in the United States. It develops and commercializes platforms for performing minimally invasive surgical procedures in the brain under magnetic resonance imaging guided interventions. The company offers ClearPoint system, an integrated system for the insertion of deep brain stimulation electrodes, biopsy needles, and laser catheters, as well as the infusion of pharmaceuticals into the brain.